This COST action will provide the following scientific results to allow :
- better understanding of aldosterone synthesis in normal and pathological conditions relating to adrenal tumours, hyperaldosteronism;
- insights into the mechanisms of activation of MR (structure-function relationship, post translational modifications, co-regulators);
- increasing knowledge of molecular and pathophysiological consequences of MR activation in vivo (identification of novel cellular targets, novel signalling pathways, novel pathophysiological roles);
- defining clinical situations where MR activation occurs with potentially new applications of MR antagonists;
- identifying and validating susceptibility markers (genotype) or biological markers of MR activation (biomarkers) in order to better identify/stratify and follow patients for personalized treatment with MR antagonists.
This COST action will provide the following societal results :
- Improved therapies of life-threatening diseases such as cardiovascular/renal/metabolic diseases reducing health cost and improving patient’s quality of life;
- knowledge transfer to European SMEs for the development of novel therapeutic targets or diagnostic tools.
This COST action will provide the scientific community with a well-trained and networked cohort of Early Stage Researchers (ESRs) within European and Third countries. Researcher exchanges through short term scientific missions (STSM) will further strengthen the future of European and third countries research in the field; retention of talented ESR, particularly female researchers, with increased opportunity to establish novel research groups in multidisciplinary aspects of the field; interdisciplinary knowledge and skills transfer among participants; creating networks, tools and relationships that will persist after the COST Action. Moreover, the international impact of this network will attract talented ESRs worldwide, thus strengthening the European Research Area for the future.
It is estimated that 150 ESRs from 10 countries will be involved in this COST Action. Therefore, we anticipate about 8-10 STSM annually (depending on duration of the exchange), including ESRs and senior researchers. This means that 1/4 of the participant laboratories will play a partner role each year in an Exchange either through sending a student/senior or receiving a student/senior in their laboratory. As a proof of principle, some partners of this Action have already begun to exchange ESRs (France-Ireland, France-Germany, France-Chile, Ireland-Chile).
Exploitation of the results
This COST action will aim for maximally productive outcomes by:
- widespread engagement through publicity of the Action within the public domain and in several specialized scientific societies (cardiovascular, endocrine, experimental biology, physiology etc), international meetings, and publications;
- performance management of work groups;
- summer schools with internationally recognized invited speakers within and outside the field;
- competitive gender balanced STSMs for ESRs into associated laboratories;
- dissemination of results and actions through a specific website and the scientific press.